Selling, General, and Administrative Costs: Novartis AG vs Agios Pharmaceuticals, Inc.

A Tale of Two Companies: SG&A Expenses Over Time

In the world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability and competitiveness. This chart provides a fascinating comparison between Novartis AG and Agios Pharmaceuticals, Inc. from 2014 to 2023.

Novartis AG, a global healthcare giant, consistently reported SG&A expenses in the range of $12.5 billion to $16.5 billion annually. Despite fluctuations, their expenses remained relatively stable, reflecting their robust market presence and operational scale. In contrast, Agios Pharmaceuticals, a smaller biotech firm, showed a significant upward trend in SG&A expenses, increasing by over 500% from 2014 to 2020. This growth highlights Agios's aggressive expansion and investment in marketing and administrative capabilities.

Understanding these trends offers valuable insights into the strategic priorities and financial health of these companies, providing a window into their operational strategies and market dynamics.